Question · asked by 1 review

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo: Leaving the study early

Population
18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder + antipsychotic‐induced tardive dyskinesia
Intervention
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine)
Comparison
placebo
Outcome
Leaving the study early

It is very uncertain whether ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) changes leaving the study early compared with PLACEBO (very low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs PLACEBO
Leaving the study early · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
It is very uncertain whether ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) changes leaving the study early compared with PLACEBO (very low certainty).
Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia (2018) · Cochrane Headline outcomes only
RR 1 [0.31, 3.25]1 study · 102 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia
2018 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.